Back to top
more

Concert Pharmaceuticals, Inc. (CNCE)

(Delayed Data from NSDQ)

$10.65 USD

10.65
228,845

+0.69 (6.93%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.67 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[CNCE]

Reports for Purchase

Showing records 1 - 20 ( 114 total )

Industry: Medical - Drugs

Record: 1

03/01/2023

Industry Report

Pages: 3

Event Driven A.M. Note

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

11/22/2022

Daily Note

Pages: 4

Potential for Faster Adoptability for deuruxolitinib?Takeaways from the World Congress

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

11/08/2022

Company Report

Pages: 6

Pivotal Trials Support Deuruxolitinib?s Best-in-Class Potential; Reit. Buy and $17 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

09/12/2022

Daily Note

Pages: 4

EADV Data Demonstrate CTP-543''s Superior Efficacy and Safety Profile?Our Thoughts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

08/05/2022

Company Report

Pages: 6

Thoughts on CTP-543?s Best-in-Class Potential, Launch, and IPR Issues

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

08/01/2022

Daily Note

Pages: 4

Concert Ready For NDA Filing in 1H 2023 With THRIVE-AA1 and AA2 Win

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

05/23/2022

Daily Note

Pages: 4

CTP-543 THRIVE-AA1 Data Shows Persistence Pays - Thoughts on Best-in-Class Opportunity

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

05/06/2022

Company Report

Pages: 6

Considerations on CTP-543 Registrational Trial Read-outs

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

03/04/2022

Company Report

Pages: 6

Expecting CTP-543 to Thrive in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

11/10/2021

Company Report

Pages: 6

CTP-543 THRIVE-AA Program Can Deliver-Looking to Data in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CNCE

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

08/06/2021

Company Report

Pages: 6

CTP543 is Well Positioned Ahead of Phase 3 Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

07/02/2021

Daily Note

Pages: 4

CTP-543 Hair Regrowth Here To Stay, OLE Data Supports Durability

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

05/18/2021

Daily Note

Pages: 4

Milestone Monetization Paves Cash Runway Into 2Q22; THRIVE-AA Trials Proceed

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

05/05/2021

Company Report

Pages: 6

Phase 3 THRIVE-AA Progress Continues to Thrive; Topline Expected 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

03/04/2021

Daily Note

Pages: 4

Baricitinib Data Demonstrate Superior Efficacy and Safety Profile of CTP-543?Our Insights

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

02/26/2021

Company Report

Pages: 6

Concert Keeps the Focus on CTP-543: Our Take from 4Q Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

02/02/2021

Company Report

Pages: 6

CTP-543 Offers Perspective for Deuterium Platform Following ?692 Top Line; PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

11/06/2020

Company Report

Pages: 6

Supercharged Concert on Track with CTP-692 and CTP-543; Reit Buy and PT $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party
// eof